Abstract
Two consecutive cases of symptomatic vitreomacular adhesion with macular hole were treated with intravitreal ocriplasmin. Both were complicated by long-term visual symptoms and chronic serous foveal detachments lasting 17 months post-treatment. These findings suggest direct and long-lasting effects of ocriplasmin on the retinal pigment epithelium and/or outer retina. Patients treated with ocriplasmin should be cautioned that the side effects of even successful drug treatment may prolong visual recovery compared to vitrectomy.
[Ophthalmic Surg Lasers Imaging Retina. 2015;46:976–978.]
- 1.U.S. Food and Drug Administration. FDA approves Jetrea for symptomatic vitreomacular adhesion in the eyes. FDA website. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm324369.htm. Published October 18, 2012. Google Scholar
- 2.Stalmans P, Benz MS, Gandorfer A, MIVI-TRUST Study Group. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med. 2012; 367(7):606–615.
10.1056/NEJMoa1110823 Crossref Medline, Google Scholar - 3.Chan CK, Wessels IF. Delayed subretinal fluid absorption following pneumatic retinopexy. Ophthalmology. 1989; 96(12):1691–1700.
10.1016/S0161-6420(89)32660-1 Crossref Medline, Google Scholar - 4.Tibbets MD, Reichel E, Witkin AJ. Vision loss after intravitreal ocriplasmin: correlation of spectral-domain optical coherence tomography and electroretinography. JAMA Ophthalmol. 2014; 132(4):487–490.
10.1001/jamaophthalmol.2013.8258 Crossref Medline, Google Scholar - 5.Fahim AT, Khan NW, Johnson MW. Acute panretinal structural and functional abnormalities after intravitreous ocriplasmin injection. JAMA Ophthalmol. 2014; 132(4):484–486.
10.1001/jamaophthalmol.2013.8142 Crossref Medline, Google Scholar
